Clinical Significance of Red Distribution Width to Platelet Ratio in Evaluation of Hepatic Fibrosis in Metabolic Dysfunction Associated Fatty Liver Disease

Authors

1 Internal Medicine, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt

2 Gastroentrology and Hepatology, National Hepatology and Tropical Medicine Research Institute, Al-Azhar University, Cairo, Egypt

Abstract

Background: In 2020, the abbreviation "metabolic dysfunction-associated fatty liver diseases" (MAFLD) was employed to denote hepatic steatosis associated with systemic metabolic dysfunction. Aim and objectives: To evaluate the diagnostic and clinical use of the width of red cell distribution to platelet ratio as a noninvasive surrogate marker for liver stiffness in fatty liver diseases linked to metabolic dysfunction. Patients and methods: The current cross-sectional study was carried out on 100 MAFLD patients presented in the MAFLD outpatients' clinic, National Hepatology and Tropical Medicine Research Institute (NHTMRI) incorporation with El-Hussein University hospital-internal medicine department from March to August 2023. Results: The highest mean value of Red cell distribution width to platelet ratio (RPR) was higher in Fibrosis F4 (0.107±0.016), followed by Fibrosis F3 (0.098±0.013), then Fibrosis F2 (0.070±0.025), with the most negligible value recorded in F1 (0.044±0.012). RPR can be a noninvasive diagnosis indicator for predicting extensive fibrosis in patients with NAFLD. Conclusion: RPR is a straightforward and readily accessible measure for estimating the severity of MAFLD disease. When predicting MAFLD, the RPR index outperforms FAST, FIB-4, and APRI due to its greater AUC. In patients with MAFLD, RPR can be employed as a noninvasive diagnosis marker to forecast severe fibrosis.

Files

Share

How to cite

Statistics